Work

Abstract 5599: NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, blocks YAP1 signaling in NSCLC cell lines

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-5599

Authors: Boback Kaghazchi, Inigo Lanzagorta Calvillo, Ben King, Enrique Poradosu, Neil O Carragher, Asier Unciti-Broceta

Institution: University of Edinburgh

Language: English

Topic: Hippo pathway signaling and YAP/TAZ

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409629582

Cites:

Cited by:

Related to: 10